BIOPHYTIS (EPA:ALBPS) - Results of the Combined General Meeting on May 10, 2021 All ordinary and extraordinary resolutions have been adopted

Transparency directive : regulatory news

11/05/2021 08:00

Press release

Results of the Combined General Meeting on May 10, 2021
All ordinary and extraordinary resolutions have been adopted

Paris, France, Cambridge (Massachusetts, United States), May 11, 2021, 8:00 am.
CEST - - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS),
("Biophytis" or the "company"), - Biophytis SA (NasdaqCM: BPTS, Euronext Growth
Paris: ALBPS), a clinical-stage biotechnology company focused on the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19 today announces the approval by a very large
majority of all resolutions falling within the remit of the Combined General
Meeting.

Biophytis' combined AGM took place today behind closed doors, due to the
COVID-19 pandemic.

2077 shareholders participated to the vote, holding collectively 24 994 687
shares, or a quorum of 22.37% and 22.82% of the voting rights. The 31
resolutions were approved at a majority of over 80% and were comprising in
particular those ratifying the unconsolidated and consolidated accounts for
fiscal year 2020 and the allocation of profit & loss for the fiscal year ended
December 31, 2020 as well as extraordinary resolutions.

Stanislas Veillet, President and CEO of Biophytis, said: "I am very pleased
that all the resolutions of the Combined General Meeting were approved by a
very large majority. I would like to warmly thank all shareholders for their
exceptional commitment that made it possible for us to hold this General
Meeting and for their confidence in Biophytis by supporting at a majority of
over 80% each resolution put to the vote."

The results of the votes of the combined General Meeting will be available on
Biophytis' website from May 11, 2021, under the section - Investors - General
Assembly
https://www.biophytis.com/en/action/assemblees-generales/
assemblee-generale/

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, being developed as a treatment for sarcopenia in a Phase 2
clinical trial in the United States and Europe (SARA-INT). It is also being
studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of
severe respiratory manifestations of COVID-19 in Europe, Latin America, and the
US. A pediatric formulation of Sarconeos (BIO101) is being developed for the
treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris,
France, and Cambridge, Massachusetts.
The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN:
FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS - ISIN:
US09076G1040). For more information visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. These forward-looking statements include statements regarding
Biophytis' anticipated timing for its Interim Analysis of Part 1 and release of
full study results. Such forward-looking statements are based on assumptions
that Biophytis considers to be reasonable. However, there can be no assurance
that the statements contained in such forward-looking statements will be
verified, which are subject to various risks and uncertainties including,
without limitation, delays in patient recruitment or retention, interruptions
in sourcing or supply chain, its ability to obtain the necessary regulatory
authorizations, COVID-19-related delays, and the impact of the current pandemic
on the Company's clinical trials. The forward-looking statements contained in
this press release are also subject to risks not yet known to Biophytis or not
currently considered material by Biophytis. Accordingly, there are or will be
important factors that could cause actual outcomes or results to differ
materially from those indicated in these statements. In France, please also
refer to the "Risk Factors" section of the Company's Annual 2020 Report
available on BIOPHYTIS website https://www.biophytis.com/. We undertake no
obligation to publicly update or review any forward-looking statement, whether
as a result of new information, future developments or otherwise, except as
required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Ligia Vela-Reid
E: lvela-reid@lifesciadvisors.com

BIOPHYTIS's latest news

14/05/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Results of the Combined General Meeting on May 10, 2021 All ordinary and extraordinary resolutions have been adopted

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories